(Reuters) – AstraZeneca (LON: AZN) Plc said Monday that it has begun registering volunteers to participate in a US-funded late-stage trial of an experimental COVID-19 vaccine.
The tests will be attended by 30,000 people.
Participants will receive either two doses of the experimental vaccine, AZD1222, four weeks apart, or a placebo, the company said.
AZD1222 is already undergoing late-stage trials in the UK, Brazil and South Africa, with additional studies planned in Japan and Russia. In total, up to 50,000 people around the world can take part in the tests.
Trials in the United States will assess whether the vaccine can prevent COVID-19 infection or help avoid severe illness, the US National Institutes of Health said in a statement.
The researchers will also assess whether the vaccine can reduce the frequency of emergency department visits due to COVID-19.
(Manojna Maddipatla in Bangalore, translated by Elizaveta Zhuravleva. Editor Marina Bobrova)